Key result
Anticoagulants linked to ~361% higher infective endocarditis risk in prosthetic valves, with no antiaggregant protection.
Why the study?
Antiaggregants could prevent infective endocarditis in preclinical studies, but whether antiaggregants or anticoagulants are also protective in humans was unknown.
Do antiaggregant or anticoagulant therapies prevent infective endocarditis in patients with native or bioprosthetic aortic valves?
Do antiaggregant or anticoagulant therapies prevent infective endocarditis in patients with native or bioprosthetic aortic valves?
Contrary to preclinical studies, antiaggregants and anticoagulants were not protective against infective endocarditis in humans and were instead associated with higher IE occurrence, likely due to confounding by indication.
Answers are grounded in this paper and cite their sources.
Anticoagulants were associated with higher endocarditis risk without antiaggregant benefit; hypothesis-generating and should not yet change practice.
Objective: Antiaggregants (Ag) could prevent infective endocarditis (IE) in preclinical studies. In this study we investigated whether Ag or anticoagulants (Ac) were also protective in humans. Methods: In part I we determined the incidence of IE of bioprosthetic aortic valves (PVE) in 333 consecutive patients who underwent aortic valve replacement for noninfective aortic insufficiency between 2009 and 2019. In part II we retrospectively analyzed data of 137 patients who had developed IE of the native aortic valve (NVE) between 2007 and 2015. Multivariable Fine-Gray and logistic regression models were used to investigate associations between Ag and Ac therapy and IE. Results: Sixteen of 333 (4.8%) aortic valve replacement recipients developed PVE after a median of 3.72 years. There was no association between Ag and PVE, whereas Ac was associated with a higher IE occurrence (no association for vitamin K antagonists but significant for fondaparinux or low molecular-weight heparins; hazard ratio, 4.61; 95% CI, 1.01-21.9). In contrast, among the 137 patients in part II, vitamin K antagonists (odds ratio [OR], 7.52; 95% CI, 2.51-22.6), double antiplatelet therapy (OR, 44.3; 95% CI, 4.83-407), novel oral Ac (OR, 4.17; 95% CI, 1.15-15.1), and fondaparinux or low molecular-weight heparins (OR, 9.87; 95% CI, 1.81-53.9), but not acetylsalicylic acid, were associated with NVE. Conclusions: Ac were associated with IE in both cohorts, whereas Ag were not associated with PVE. This might reflect differences in the studied populations, with Ag and Ac being prescribed for conditions associated with long-term IE risk in the NVE cohort. Therefore, determining the potential protective effect of Ag and Ac will necessitate further well-controlled studies.
No takes yet. Share an insight, caveat, or question.
Theys et al. (2021) studied this question. Anticoagulants were associated with higher infective endocarditis risk in prosthetic and native valves, whereas antiaggregants showed no protective effect.
Synapse has enriched 10 related papers. Consider them for comparative context: